Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Visit our Heart Failure Management Hub to discover a range of educational content to facilitate the use of SGLT-2 inhibitors and other guideline directed medical therapies as foundational treatment for HF.


Post-extrasystolic Potentiation: Link between Ca2+ Homeostasis and Heart Failure?


Arrhythmia & Electrophysiology Review 2016;5(1):20–6

The European Heart Rhythm Association: A Myriad of Benefits and Privileges


Arrhythmia & Electrophysiology Review 2016;5(2):82

Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes


Arrhythmia & Electrophysiology Review 2016;5(2):90–101

Antiarrhythmic Drug Therapy to Avoid ICD Shocks


Arrhythmia & Electrophysiology Review 2016;5(2):117–21